PTPN11 and melanoma: SHP2 is upstream of the alternate pathways, such as AKT and mTOR, and is employed by BRAFi–MEKi double-resistant melanoma samples, suggesting that SHP2 inhibition can effectively treat BRAFi and MEKi double-resistant cells.